|
[pick list]
[Dear]
[Hello]
[pick list]
[Dr. Last Name],
[First Name],
[First Name Last Name],
|
[pick list]
[I wanted to reach out and share some helpful information around the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for pralsetinib (GAVRETO).]
[I wanted to follow up on our last conversation. Below is some helpful information about the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for pralsetinib (GAVRETO).]
[I'd like to share some helpful information about the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for pralsetinib (GAVRETO).]
|
|
The NCCN Guidelines® recommend pralsetinib (GAVRETO) as a Category 2A:
|
preferred treatment option for first-line RET fusion-positive metastatic NSCLC1*
|
|
|
preferred treatment option for select patients with recurrent/persistent locoregional or distant metastatic RET mutation-positive MTC2†
|
|
|
systemic treatment option for structurally persistent/recurrent locoregional or distant metastatic RET fusion-positive PTC not amenable to RAI therapy2
|
|
|
GAVRETO is the only once-daily targeted RET therapy indicated for3:
|
|
Adult patients with RET fusion+ mNSCLC as detected by an FDA approved test
|
|
|
Patients 12 years+ with advanced or metastatic RET-mutant MTC who require systemic therapy
|
|
|
Patients 12 years+ with advanced or metastatic RET fusion+ thyroid cancer who require systemic therapy and are RAI refractory
|
|
|
These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.
|
|
Select safety information
|
|
Serious and sometimes fatal adverse reactions occurred with GAVRETO. Warnings and precautions include interstitial lung disease/pneumonitis, hypertension, hepatotoxicity, hemorrhagic events, tumor lysis syndrome, risk of impaired wound healing, and embryo-fetal toxicity.
|
|
Please see additional Important Safety Information below and full Prescribing Information.
|
|
|
|
|
|
I’m including some additional information that you may find useful.
|
|
|
[Fragment/attachment pick list]
|
[GAVRETO RET+ mNSCLC and Advanced Thyroid Cancer Product Brochure]
|
|
|
|
[GAVRETO RET+ mNSCLC Product Brochure]
|
|
|
|
[GAVRETO mNSCLC Treatment-Naïve Update Overview]
|
|
|
|
[GAVRETO Website for Healthcare Professionals]
|
|
|
|
|
I would be happy to set up a quick
[pick list]
[falsemeetingtruecalltruevideo chat]
to answer any questions around the GAVRETO sampling program.
|
[pick list]
[Sincerely],
[Best],
|
|
[Rep photo]
|
[pick list]
[Rep name]
[Rep title]
Blueprint Medicines
[Rep phone number]
[Rep email address]
|
|
|
Select safety information
|
|
Interstitial Lung Disease (ILD)/Pneumonitis occurred in 10% of patients who received GAVRETO, including 2.7% with Grade 3/4, and 0.5% with fatal reactions. Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Withhold GAVRETO and promptly investigate for ILD in any patient who presents with acute or worsening of respiratory symptoms (e.g., dyspnea, cough, and fever). Withhold, reduce dose or permanently discontinue GAVRETO based on severity of confirmed ILD.
|
|
Hypertension occurred in 29% of patients, including Grade 3 hypertension in 14% of patients. Overall, 7% had their dose interrupted and 3.2% had their dose reduced for hypertension. Treatment-emergent hypertension was most commonly managed with anti-hypertension medications. Do not initiate GAVRETO in patients with uncontrolled hypertension. Optimize blood pressure prior to initiating GAVRETO. Monitor blood pressure after 1 week, at least monthly thereafter and as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue GAVRETO based on the severity.
|
|
Hepatotoxicity: Serious hepatic adverse reactions occurred in 2.1% of patients treated with GAVRETO. Increased aspartate aminotransferase (AST) occurred in 69% of patients, including Grade 3/4 in 5% and increased alanine aminotransferase (ALT) occurred in 46% of patients, including Grade 3/4 in 6%. The median time to first onset for increased AST was 15 days (range: 5 days to 1.5 years) and increased ALT was 22 days (range: 7 days to 1.7 years). Monitor AST and ALT prior to initiating GAVRETO, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Withhold, reduce dose or permanently discontinue GAVRETO based on severity.
|
|
Grade ≥ 3 hemorrhagic events occurred in 2.5% of patients treated with GAVRETO including one patient with a fatal hemorrhagic event. Permanently discontinue GAVRETO in patients with severe or life-threatening hemorrhage.
|
|
Tumor Lysis Syndrome (TLS): Cases of TLS have been reported in patients with medullary thyroid carcinoma receiving GAVRETO. Patients may be at risk of TLS if they have rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration. Closely monitor patients at risk, consider appropriate prophylaxis including hydration, and treat as clinically indicated.
|
|
Impaired wound healing can occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore, GAVRETO has the potential to adversely affect wound healing. Withhold GAVRETO for at least 5 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of GAVRETO after resolution of wound healing complications has not been established.
|
|
Based on findings from animal studies and its mechanism of action, GAVRETO can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with GAVRETO and for 2 weeks after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with GAVRETO and for 1 week after the final dose. Advise women not to breastfeed during treatment with GAVRETO and for 1 week after the final dose.
|
|
Common adverse reactions (≥25%) were constipation, hypertension, fatigue, musculoskeletal pain and diarrhea. Common Grade 3/4 laboratory abnormalities (≥2%) were decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased phosphate, decreased calcium (corrected), decreased sodium, increased AST, increased ALT, decreased platelets and increased alkaline phosphatase.
|
|
Avoid coadministration of GAVRETO with strong CYP3A inhibitors or combined P-gp and strong CYP3A inhibitors. If coadministration cannot be avoided, reduce the GAVRETO dose. Avoid coadministration of GAVRETO with strong CYP3A inducers. If coadministration cannot be avoided, increase the GAVRETO dose.
|
|
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
|
|
Please click here to see the full Prescribing Information for GAVRETO.
|
|
|
